Is Pregabalin Good for Arthritis Pain?

Pregabalin is not approved for arthritis and is not broadly effective as an arthritis painkiller in the way that anti-inflammatories or standard analgesics are. However, a meaningful fraction of people with arthritis develop pain that behaves more like nerve pain than joint inflammation, and pregabalin targets exactly that kind of pain. The question of whether it helps depends less on the arthritis diagnosis itself and more on what type of pain you’re actually experiencing, which makes the honest answer more nuanced than a simple yes or no.

How Pregabalin Works and Why It Might Matter for Joints

Pregabalin was designed for nerve-related conditions like epilepsy and neuropathic pain. It binds to a specific protein on voltage-gated calcium channels in the nervous system, which dials down the release of certain chemical messengers involved in pain signaling.¹ Molecular studies have confirmed that this protein is essentially the sole target responsible for pregabalin’s painkilling effects in nerve pain.² That mechanism explains why pregabalin works well for conditions like diabetic nerve pain and postherpetic neuralgia, but it also explains why it wouldn’t necessarily help a swollen, inflamed joint. Pregabalin doesn’t reduce inflammation. It quiets overactive nerve signals.

So why would anyone consider it for arthritis? Because the pain of arthritis, especially when it becomes chronic, doesn’t always come from the joint itself.

The Neuropathic Side of Arthritis Pain

Arthritis pain is commonly thought of as joint inflammation and cartilage breakdown causing an aching, stiff joint. That’s accurate for many people, especially early on. But chronic arthritis can rewire the nervous system. Repeated pain signals from a damaged joint can cause the spinal cord and brain to amplify incoming signals, a process called central sensitization. Once that happens, the pain system itself becomes part of the problem. You feel more pain than the joint damage alone would justify, and the pain starts behaving differently: it might feel burning, tingling, shooting, or electric rather than the typical deep ache of a worn joint.³

This isn’t rare. A meta-analysis pooling data from multiple studies found that roughly 20 to 40 percent of people with knee osteoarthritis scored positive on screening tools for neuropathic-like pain, depending on which questionnaire was used. The prevalence of central sensitization features was around 36 percent.⁴ Neuroimaging studies have confirmed that in this subset, the brain’s pain-processing circuitry shows reduced inhibition and increased facilitation of pain signals, meaning the central nervous system is genuinely amplifying the pain rather than the patient simply being “sensitive.”⁵

This is the opening that makes pregabalin potentially relevant. If your arthritis pain is partly driven by sensitized nerves rather than purely by an inflamed joint, a drug that calms overactive nerve signaling could, in theory, help where anti-inflammatories alone fall short.

What the Evidence Says for Osteoarthritis

The short version: the evidence for pregabalin in osteoarthritis is thin and mixed, but it gets more encouraging when the drug is combined with a standard anti-inflammatory rather than used alone. A recent systematic review and meta-analysis of randomized controlled trials in knee osteoarthritis found that pregabalin combined with an NSAID led to meaningful functional improvement, but the reduction in pain scores was only a non-significant trend.⁶ In other words, people moved better and their joints functioned better when pregabalin was added to their NSAID, but the pain relief on its own didn’t quite clear the bar for statistical significance. Pregabalin alone was less effective than the combination approach.

Earlier, smaller studies have shown similar patterns. Research in hand osteoarthritis found that pregabalin combined with an NSAID outperformed either drug alone for arthritic pain.⁷ A comparative trial in knee osteoarthritis randomized patients into three groups receiving naproxen alone, naproxen plus duloxetine, or naproxen plus pregabalin, and measured outcomes with standard pain and function scales.⁸

Despite these hints, major guideline reviews have concluded that the evidence for using gabapentinoids like pregabalin in osteoarthritis is insufficient.⁹ That doesn’t mean it never helps anyone. It means the average patient with osteoarthritis shouldn’t expect pregabalin to make a noticeable difference, and it shouldn’t be a first-line choice. The gap between “some patients benefit” and “guideline-recommended therapy” is exactly where this drug sits for OA.

Evidence in Rheumatoid Arthritis

Rheumatoid arthritis involves a different mechanism from osteoarthritis — it’s an autoimmune condition where the immune system attacks joint linings — but persistent pain and neuropathic features can develop here too. A study comparing RA patients who received pregabalin alongside their standard disease-modifying drugs and NSAIDs versus those on standard treatment alone found that the pregabalin group had meaningfully greater reductions in pain scores by five weeks. Neuropathic pain indicators also improved substantially in the pregabalin group, with scores on the DN4 neuropathic pain questionnaire dropping from an average of about 5.2 down to 2.3, compared with minimal change in the control group.¹⁰

Those results are encouraging, but they come from preliminary research presented at a conference rather than a large definitive trial. The study population was specifically RA patients who already showed features of neuropathic pain. This is a recurring theme with pregabalin in arthritis: it looks most promising in people who have neuropathic pain features on top of their arthritis, and far less interesting in people whose pain is purely inflammatory.

Around Joint Replacement Surgery

Joint replacement is one of the most common surgical procedures performed for end-stage arthritis, and pregabalin has been studied as a way to manage pain during recovery. Here the results are genuinely mixed, and the context matters a lot.

A systematic review and meta-analysis looking at pregabalin for pain after total hip and knee replacements found that it modestly reduced pain during movement at 24, 48, and 72 hours after surgery and cut opioid use over those first three days. By 72 hours, patients on pregabalin also showed better range of motion.¹¹ That paints a cautiously positive picture for the immediate postoperative window.

But other individual trials tell a different story. A well-designed randomized trial testing multiple pregabalin doses (50, 100, and 150 mg) against placebo after total knee replacement found that pregabalin did not reduce pain at rest, during walking, or during knee bending at two weeks. It didn’t cut opioid use. It didn’t help with chronic pain down the line. What it did do was increase drowsiness and reduce patient satisfaction at two weeks.¹²

On the other hand, when pregabalin was started before surgery and continued through early recovery, one randomized trial found that it eliminated neuropathic pain at three and six months after knee replacement. No patients in the pregabalin group developed chronic neuropathic pain, compared with about 5 to 9 percent in the placebo group. The pregabalin group also used fewer opioids and recovered more knee flexion over the first 30 days.¹³

The discrepancy between these studies probably reflects timing, dose, and patient selection. Starting pregabalin before the surgical injury and continuing it through the period when the nervous system is most vulnerable to sensitization seems more effective than adding it only after surgery has already happened. The perioperative strategy targets the nerve-sensitization window rather than trying to treat pain that’s already established.

Combination Therapy Versus Monotherapy

A consistent pattern runs through the arthritis literature on pregabalin: it works better as an add-on than as a standalone treatment. The meta-analysis of knee OA trials found that combination therapy with an NSAID produced meaningful functional gains, while pregabalin monotherapy was less effective.⁶ This makes sense given the underlying biology. Arthritis pain is rarely purely neuropathic. There’s usually some ongoing inflammation, mechanical stress, or both. An anti-inflammatory drug addresses the joint-level drivers while pregabalin can target any amplified nerve signaling on top. Neither covers the other’s territory well on its own.

For anyone whose doctor is considering pregabalin for arthritis, this distinction matters practically. If you’re already on an NSAID or other conventional arthritis treatment and still experiencing pain with nerve-like qualities, adding pregabalin is a more evidence-supported move than switching to pregabalin instead of your current treatment.

Side Effects That Matter Especially for Arthritis Patients

Pregabalin’s most common side effects are dizziness (reported in roughly 30 percent of patients in some studies), drowsiness (around 18 percent), weight gain, and peripheral edema — swelling in the hands and feet.¹⁴ Each of these has specific implications for arthritis patients that are worth thinking through.

Dizziness and balance problems are particularly concerning if you already have limited mobility or joint instability from arthritis. Pregabalin can impair gait and balance, and these effects raise the risk of falls. That risk is elevated in older adults: analyses of adverse event databases found that people aged 60 and older had a significantly higher rate of fall-related side effects compared to younger patients taking the drug.¹⁵ Given that osteoarthritis is overwhelmingly a condition of middle-aged and older adults, this overlap in risk populations deserves attention. A fall when you already have a compromised knee or hip joint can be catastrophic.

Weight gain is another issue. Even a few extra pounds increase the mechanical load on arthritic weight-bearing joints, potentially worsening the structural aspect of the disease. Peripheral edema could also be confused with joint swelling, complicating your or your doctor’s ability to tell whether the arthritis itself is flaring.

Dependence and Withdrawal

Pregabalin is a controlled substance in many countries, and for good reason. Though it’s not an opioid, it can produce dependence, especially with long-term use or at higher doses. A case report describes a 55-year-old woman who developed pregabalin dependence after 10 years of use for chronic back pain, highlighting the difficulty of managing long-term reliance on the drug.¹⁶

Withdrawal symptoms after stopping pregabalin abruptly can be unpleasant and occasionally dangerous. A systematic review of gabapentinoid misuse found that among patients who reported pregabalin misuse, nearly half had experienced withdrawal symptoms. Those symptoms can include anxiety, insomnia, tremors, sweating, and in severe cases, seizures.¹⁷ The withdrawal concern is most acute when doses are supratherapeutic or when the drug is stopped suddenly rather than tapered, but it’s worth knowing about before starting a medication you might be on indefinitely for a chronic condition like arthritis.

This doesn’t mean pregabalin should be avoided entirely. Used at standard doses under medical supervision and tapered gradually if discontinued, the risk is manageable. But it does mean you should have an honest conversation with your doctor about exit strategies before you start.

Predicting Who Will Respond

One of the more useful findings in the pregabalin literature involves predicting who is likely to benefit before committing to a trial of the drug. Research using the Pain Quality Assessment Scale found that certain pain descriptors predicted pregabalin response with reasonable accuracy. Patients whose pain had qualities like electric, tingling, cramping, or radiating sensations were significantly more likely to respond. When these pretrial scores were plugged into a prediction model, the tool correctly identified responders about 77 percent of the time and non-responders about 83 percent of the time.¹⁸

In practical terms, if your arthritis pain is mostly a dull, deep ache that worsens with use and improves with rest, pregabalin is probably not going to move the needle much. That kind of pain is largely mechanical and inflammatory, and it responds better to anti-inflammatories, physical therapy, and joint protection strategies. But if your pain includes burning, tingling, shooting, or electric sensations, or if it persists even when the joint is at rest and appears disproportionate to what imaging shows, those are signs of neuropathic involvement. That’s the phenotype where pregabalin has the most to offer.

Neuroimaging research reinforces this stratification. OA patients identified as having central sensitization features on simple screening questionnaires showed distinct brain patterns confirming that their pain was being amplified centrally. Those same patients also had worse outcomes after joint replacement surgery.⁵ For this group, addressing the nervous-system component of pain — potentially with a drug like pregabalin — may be important not just for comfort but for improving surgical results if replacement is on the table.

Why It Keeps Getting Prescribed Off-Label

Despite insufficient evidence for a blanket recommendation, pregabalin continues to be prescribed off-label for arthritis pain. A review of gabapentinoid prescribing practices at a large academic medical center found that osteoarthritis was among the pain conditions for which gabapentinoids were prescribed despite lacking substantial evidence.⁹ Several factors drive this. NSAIDs have their own ceiling of effectiveness and can’t be used safely long-term in many patients because of stomach, kidney, and cardiovascular risks. Opioids are increasingly restricted and carry well-known problems. Duloxetine is approved for chronic musculoskeletal pain and is another option, but it doesn’t work for everyone. Pregabalin fills a niche for clinicians looking for something to add when first-line treatments haven’t been enough.

Whether that niche is justified depends on the individual. For a 70-year-old with knee osteoarthritis whose pain is well-explained by X-ray findings and responds reasonably to anti-inflammatories, adding pregabalin introduces side effects without strong evidence of benefit. For a 55-year-old with rheumatoid arthritis who scores high on neuropathic pain questionnaires and gets only partial relief from disease-modifying drugs and NSAIDs, the preliminary evidence is more supportive, especially as an add-on. The drug hasn’t earned a general recommendation for arthritis, but the biology of pain sensitization means it has a genuine role in selected cases where the nervous system has become part of the problem.

1
PubMed. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery
2
PubMed Central. Mechanisms of the gabapentinoids and α2δ‐1 calcium channel subunit in neuropathic pain
3
PubMed Central. Mechanisms of Peripheral and Central Sensitization in Osteoarthritis Pain
4
Osteoarthritis and Cartilage. Systematic review and meta-analysis of the prevalence of neuropathic-like pain and/or pain sensitization in people with knee and hip osteoarthritis
5
PubMed Central. Central Sensitization in Knee Osteoarthritis: Relating Presurgical Brainstem Neuroimaging and Pain DETECT ‐Based Patient Stratification to Arthroplasty Outcome
6
Springer Nature. The effect of pregabalin on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials
7
PubMed Central. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis
8
PubMed Central. Multimodal Pain Management in Knee Osteoarthritis: A Comparative Study of Pregabalin and Duloxetine as Adjuncts to Naproxen
9
Mayo Clinic Proceedings: Innovations, Quality & Outcomes. Gabapentinoid Prescribing Practices at a Large Academic Medical Center
10
Annals of the Rheumatic Diseases. PREGABALIN EFFICACY IN THE TREATMENT OF CHRONIC PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS
11
PubMed Central. Efficacy and safety of pregabalin for postoperative pain after total hip and knee arthroplasty: a systematic review and meta-analysis
12
PubMed Central. Pregabalin and pain after total knee arthroplasty: a double-blind, randomized, placebo-controlled, multidose trial
13
PubMed. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial
14
PubMed Central. The effect of pregabalin treatment on balance and gait in patients with chronic low back pain: a retrospective observational study
15
PubMed. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases
16
PubMed Central. Pregabalin Dependence and Management in a 55-Year-Old Female with Chronic Low Back Pain
17
PubMed Central. Misuse of Pregabalin and Gabapentin: A Second Systematic Review Update
18
PubMed. Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale